Business
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submission of a Pre-IND Meeting request to the FDA on its anti-tumor Drug Candidate CANNABICS™ RCC-33, the world's first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer. The pre-IND Meeting request with the FDA is expected to be submitted during Q1 of 2021, and subsequently take place in the first half of 2021.\n\n \n \n \n \n \n \n\n \nEyal Barad, Cannabics Pharmaceuticals CEO, said: \"The company's decision to move forward with an FDA regulatory path for this specific product is based on a combination of factors including: the promising pre-clinical findings from our licensed in-house Drug Discovery platform in Israel, our proprietary related IP, and our positive market analysis. After many years of R&D and of developing our expertise in anti-cancer drug discovery, we are truly excited to have developed what we believe to be the world's first cannabinoid-based medicine targeting colorectal cancer.\"\nPrior to filing the request for a pre-IND Meeting, the company plans to carry out a Proof of Concept (POC) study using In-vivo animal models, and a completion of the synopsis of the first in-human phase 1/2a clinical study. All this in conjunction with the development of the CANNABICS™ RCC-33's clinical...